FINNENCE ▪ THE WIRE FILE
THE WIRE · № 87696
Company■ Mixed
New Phase 3 trial: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes — Eli Lilly and Company
KINDCompany
DIRECTION■ Mixed
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.
FULL DISPATCH
Sponsor: Eli Lilly and Company; Status: Not Yet Recruiting; Conditions: Obesity; Interventions: eloralintide and tirzepatide, Eloralintide, Tirzepatide; Enrollment: 2115 (estimated); First posted: 2026-10-19; NCT: NCT07881432
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTEli Lilly · LLY
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
←CORRELATIONshares LLY
New Phase 3 trial: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes — Eli Lilly and Company2026-10-19 12:00 UTC
New Phase 3 trial: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes — Eli Lilly and Company2026-10-19 12:00 UTC
←CORRELATIONshares LLY
KRAS Inhibitors Market is Set for Expansion During the Forecast Period (2026-2036) Supported by Emerging Therapies Targeting Diverse KRAS Mutations2026-10-19 14:31 UTC
KRAS Inhibitors Market is Set for Expansion During the Forecast Period (2026-2036) Supported by Emerging Therapies Targeting Diverse KRAS Mutations2026-10-19 14:31 UTC
←CORRELATIONshares LLY
Why Is Eli Lilly (LLY) Being Sued Over Alleged Insulin Price Inflation?2026-10-19 16:15 UTC
Why Is Eli Lilly (LLY) Being Sued Over Alleged Insulin Price Inflation?2026-10-19 16:15 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.